These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 15604125)
61. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. Norton GR; Woodiwiss AJ; Gaasch WH; Mela T; Chung ES; Aurigemma GP; Meyer TE J Am Coll Cardiol; 2002 Feb; 39(4):664-71. PubMed ID: 11849866 [TBL] [Abstract][Full Text] [Related]
62. Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats. Cerbai E; De Paoli P; Sartiani L; Lonardo G; Mugelli A J Cardiovasc Pharmacol; 2003 May; 41(5):804-12. PubMed ID: 12717113 [TBL] [Abstract][Full Text] [Related]
63. Metformin prevents the development of chronic heart failure in the SHHF rat model. Cittadini A; Napoli R; Monti MG; Rea D; Longobardi S; Netti PA; Walser M; Samà M; Aimaretti G; Isgaard J; Saccà L Diabetes; 2012 Apr; 61(4):944-53. PubMed ID: 22344560 [TBL] [Abstract][Full Text] [Related]
64. Dihydroxyflavonol reduces post-infarction left ventricular remodeling by preventing myocyte apoptosis in the non-infarcted zone in goats. Wang S; Fei K; Xu YW; Wang LX; Chen YQ Chin Med J (Engl); 2009 Jan; 122(1):61-7. PubMed ID: 19187619 [TBL] [Abstract][Full Text] [Related]
65. Effects of Xin-Ji-Er-Kang formula on 2K1C-induced hypertension and cardiovascular remodeling in rats. Guo K; Lan CZ; Yu TT; Huang LL; Wang XH; Pan C; Gao S J Ethnopharmacol; 2014 Sep; 155(2):1227-35. PubMed ID: 25063306 [TBL] [Abstract][Full Text] [Related]
66. Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. Yamamoto K; Masuyama T; Sakata Y; Nishikawa N; Mano T; Hori M J Hypertens; 2002 Apr; 20(4):753-61. PubMed ID: 11910313 [TBL] [Abstract][Full Text] [Related]
68. Effects of treatment with a 5-HT4 receptor antagonist in heart failure. Birkeland JA; Sjaastad I; Brattelid T; Qvigstad E; Moberg ER; Krobert KA; Bjørnerheim R; Skomedal T; Sejersted OM; Osnes JB; Levy FO Br J Pharmacol; 2007 Jan; 150(2):143-52. PubMed ID: 17160012 [TBL] [Abstract][Full Text] [Related]
69. Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: I. Regional hemodynamics and myocyte remodeling. Wang X; Li F; Gerdes AM J Mol Cell Cardiol; 1999 Feb; 31(2):307-17. PubMed ID: 10093044 [TBL] [Abstract][Full Text] [Related]
70. Is apoptosis present in progression to chronic hypertensive heart failure? Tamura T; Said S; Lu W; Harris J; Neufeld D; Burbach JA; Gerdes AM J Card Fail; 2000 Mar; 6(1):37-42. PubMed ID: 10746817 [TBL] [Abstract][Full Text] [Related]
71. Protein kinase C isozymes in hypertension and hypertrophy: insight from SHHF rat hearts. Johnsen DD; Kacimi R; Anderson BE; Thomas TA; Said S; Gerdes AM Mol Cell Biochem; 2005 Feb; 270(1-2):63-9. PubMed ID: 15792354 [TBL] [Abstract][Full Text] [Related]
72. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755 [TBL] [Abstract][Full Text] [Related]
73. Treatment with a growth hormone secretagogue in a model of developing heart failure: effects on ventricular and myocyte function. King MK; Gay DM; Pan LC; McElmurray JH; Hendrick JW; Pirie C; Morrison A; Ding C; Mukherjee R; Spinale FG Circulation; 2001 Jan; 103(2):308-13. PubMed ID: 11208694 [TBL] [Abstract][Full Text] [Related]
74. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Anand IS; Liu D; Chugh SS; Prahash AJ; Gupta S; John R; Popescu F; Chandrashekhar Y Circulation; 1997 Dec; 96(11):3974-84. PubMed ID: 9403622 [TBL] [Abstract][Full Text] [Related]
75. Left ventricular regional myocyte contractility in normal and heart failure states. Hinton RB; Hebbar L; Cox MH; Mukherjee R; Joshi JD; Crawford FA; Spinale FG J Mol Cell Cardiol; 1997 Jul; 29(7):1939-46. PubMed ID: 9236147 [TBL] [Abstract][Full Text] [Related]
76. Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure. Spinale FG; Johnson WS; Wang Y; Wang Z; Mukherjee R; Hebbar L; Jones BU J Card Fail; 1996 Dec; 2(4):311-8. PubMed ID: 8989646 [TBL] [Abstract][Full Text] [Related]
77. Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats. Geng J; Zhao Z; Kang W; Wang W; Zhang Y; Zhiming GE Pharmacol Res; 2010 Jan; 61(1):40-7. PubMed ID: 19683055 [TBL] [Abstract][Full Text] [Related]
78. Phosphodiesterase inhibition promotes the transition from compensated hypertrophy to cardiac dilatation in rats. Anamourlis C; Badenhorst D; Gibbs M; Correia R; Veliotes D; Osadchii O; Norton GR; Woodiwiss AJ Pflugers Arch; 2006 Jan; 451(4):526-33. PubMed ID: 16211367 [TBL] [Abstract][Full Text] [Related]
79. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation. Osadchii OE; Norton GR; McKechnie R; Deftereos D; Woodiwiss AJ Am J Physiol Heart Circ Physiol; 2007 Apr; 292(4):H1898-905. PubMed ID: 17158652 [TBL] [Abstract][Full Text] [Related]
80. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation. Veliotes DG; Woodiwiss AJ; Deftereos DA; Gray D; Osadchii O; Norton GR Hypertension; 2005 May; 45(5):914-20. PubMed ID: 15837836 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]